February 2026

The editor in chief of Evidence-Based Oncology lauds Congress' authorization of a path for Medicare coverage for multicancer early detection.

The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and multidisciplinary approaches have improved outcomes, improving quality of life.

The originator of the phase 1 drug development program at Sarah Cannon Research Institute reflects on his career.

New leaders of the Sarah Cannon Research Institute discuss its mission and priorities amid a changing landscape in community oncology.

The need for at-home caregivers in cancer care is not new. But as therapies improve, the need to care for patients with cancer stretches over longer periods. Today, the rise of advanced cellular therapies asks more of caregivers. First in a multipart series that will examine how the healthcare landscape relies on unpaid caregiving, and how alternatives are needed.

Multiple provisions of interest to patients with cancer and their physicians were included in Congress' fiscal year 2026 package, including future funding for multicancer early detection testing and a package of reforms for pharmacy benefit managers.

At the Orlando session of the Institute for Value-Based Medicine, clinicians delivering cancer care in Central Florida address restrictions from Medicare Advantage plans, which can affect access to innovative treatments for breast cancer, myeloma, and bladder cancer.

Experts discuss the impact of biomarker testing on GU and lung cancers, as well as myeloma, emphasizing its role in personalized treatment and patient care advancements.

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast cancer care and payer friction.

Teclistamab was approved to treat relapsed/refractory multiple myeloma under the FDA’s accelerated approval pathway in October 2022.

Trump's Great Healthcare Plan aims to lower drug prices, reduce insurance premiums, and enhance transparency, according to the White House.

A recent study reveals that medical debt significantly increases the risk of housing instability, highlighting urgent implications for health policy and financial security.